why choose us

First received: December 12, 2023

Clinical Trial: A Study of JNJ-87890387 for Advanced Solid Tumors

Study Status: Completed

Recruit Status: RECRUITING

Condition: Advanced Solid Tumors

Study Type: INTERVENTIONAL


Official Title: A Phase 1 Study of JNJ-87890387, an Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 (ENPP3) x CD3 Bispecific Antibody, for Advanced Solid Tumors

Brief Summary: The purpose of this study is to determine recommended phase 2 dose(s) (RP2Ds) of JNJ-87890387 and to determine the safety of JNJ-87890387 at the RP2D(s).

Read more